<DOC>
	<DOCNO>NCT02335944</DOCNO>
	<brief_summary>The study determine maximum tolerate dose ( MTD ) recommend phase 2 dose ( RP2D ) EGF816 combination INC280 estimate preliminary anti-tumor activity EGF816 combination INC280 patient advance non-small cell lung cancer ( NSCLC ) document EGFR mutation .</brief_summary>
	<brief_title>Study Safety Efficacy EGF816 Combination With INC280 Non-small Cell Lung Cancer Patients With EGFR Mutation .</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Inclusion criterion : Patients histologically document , locally advanced recurrent ( stage IIIB eligible combined modality treatment ) metastatic ( Stage IV ) nonsmall cell lung cancer Patients must locally document EGFR mutation L858R and/or ex19del , characterize de novo EGFR T790M mutation ( rare activate mutation confer sensitivity first second generation EGFR inhibitor ( e.g . L861Q , G719X , S768I ) Presence least one measurable lesion accord RECIST v.1.1 ECOG performance status ≤1 Patients must screen HBV . Patients either HBsAg positive HBVDNA positive must willing able take antiviral therapy 12 week prior 1st dose EGF816 treatment continue antiviral therapy least 4 week last dose EGF816 . Additional management patient would provide physician expertise management HBV , need . Patients must screen HCV . Patients must negative hepatitis C antibody ( HCV Ab ) HCV Ab positive undetectable level HCVRNA . Note : patient detectable HCVRNA eligible study . Phase Ib : document progression disease accord RECIST v1.1 continuous treatment EGFR TKI ( erlotinib , gefitinib afatinib ) . Phase II Group 1 ( EGFRmut , T790M , cMET , 2/4L antineoplastic , EGFR TKI resistant ) : Patients demonstrate documented clinical benefit ( CR ( duration ) , PR ( duration ) , SD least 6 month ) prior EGFR TKI ( e.g . erlotinib , gefitinib afatinib , subsequently demonstrate progression accord RECIST v1.1 . Phase II Group 2 ( EGFRmut , de novo T790M , cMET , 1/3L antineoplastic , EGFR TKI naïve ) : Advanced NSCLC patient previously treat therapy know inhibit EGFR harbor de novo T790M mutation . Phase II Group 3 ( EGFRmut , T790M negative , cMET , 1L antineoplastic ) : patient must harbor EGFR activate mutation must naïve line systemic antineoplastic therapy advance set . Phase Ib : More one previous treatment line erlotinib , gefitinib afatinib Previous treatment investigational agent know inhibit EGFR ( mutant wildtype ) Patients received three prior line antineoplastic therapy ( include EGFR TKI ) advance set . Phase II Group 1 ( EGFRmut , T790M , cMET , 2/4L antineoplastic , EGFR TKI resistant ) : More 3 prior line systemic antineoplastic therapy ( include EGFR TKI ) advance set More 1 previous treatment line 1st 2nd generation EGFR TKI ( e.g . erlotinib , gefitinib , afatinib ) advance set Previous treatment investigational market 3rd generation EGFR TKI ( e.g . AZD9291 , CO1686 , ASP8273 , EGF816 ) Previous treatment investigational market agent know inhibit EGFR ( e.g . EGF monoclonal antibody therapy , dual TKI inhibitor ) . Phase II Group 2 ( EGFRmut , de novo T790M , cMET , 1/3L antineoplastic , EGFR TKI naïve ) : More two previous treatment line systemic antineoplastic therapy advance set Previous treatment investigational market agent inhibits EGFR . EGFR inhibitor include ( limited ) generation EGFR TKI ( e.g.erlotinib , gefitinib , afatinib , AZD9291 , CO1686 , ASP8273 , EGF816 ) antiEGFR EGFR monoclonal antibody therapy dual TKI inhibitor . Phase II Group 3 ( EGFRmut , T790M negative , cMET , 1L antineoplastic ) : De novo EGFR T790M mutation identify central assessment Previous treatment systemic antineoplastic therapy advance setting ( NSCLC stage IIIB IV . Patients receive one cycle chemotherapy advance set allow ) . Previous treatment cMET inhibitor HGFtargeting therapy . Patients brain metastasis . However , patient control brain metastasis may participate trial . These patient must complete radiation therapy and/or surgery &gt; 2 week prior first dose study treatment remain asymptomatic . History another malignancy . Exception : Patients diseasefree 3 year , patient history adequately treat insitu carcinoma uterine cervix , basal squamous cell carcinoma , nonmelanomatous cancer skin , history stage IA melanoma cure , eligible . Undergone bone marrow solid organ transplant . Known history human immunodeficiency virus ( HIV ) seropositivity ( HIV test mandatory ) Patients receive concomitant immunosuppressive agent chronic corticosteroid use time study entry except control brain metastasis , topical application , inhale spray , eye drop local injection Patients clinically significant , uncontrolled cardiovascular disease Presence history interstitial lung disease interstitial pneumonitis Patients recover toxicity relate prior anticancer therapy grade ≤1 ( CTCAE v 4.03 ) Patients range laboratory value define 1 . Absolute Neutrophil Count ( ANC ) &lt; 1.5 x 109/L ( 1.5x103/µL ) 2 . Hemoglobin ( Hb ) &lt; 9 g/dL ( 90g/L ) 3 . Platelets ( PLT ) &lt; 75 x 109/L ( 75x103/µL ) 4 . Total bilirubin &gt; 1.5 x upper limit normal ( ULN ) . 5 . AST and/or ALT &gt; 3 x ULN 6 . Patients liver metastasis may include AST and/or ALT &gt; 5 xULN 7 . Alkaline phosphatase ( ALP ) &gt; 5 xULN 8 . Calculated creatinine clearance &lt; 45mL/min ( 0.75 mL/sec ) use CockroftGault formula 9 . Asymptomatic serum amylase lipase &gt; Grade 2 10 . Serum amylase serum lipase CTCAE grade ≥ 1 sign and/or symptom suggest pancreatitis pancreatic injury ( e.g . elevated Pamylase , abnormal imaging finding pancreas , etc ) Patients follow laboratory value outside laboratory normal limit correct within normal limit supplement screen : Potassium , Magnesium , Phosphorus , Total calcium ( correct serum albumin ) Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>non small cell lung cancer ,</keyword>
	<keyword>NSCLC ,</keyword>
	<keyword>EGF816 ,</keyword>
	<keyword>INC280 ,</keyword>
	<keyword>tyrosine kinase inhibitor ,</keyword>
	<keyword>c-MET</keyword>
</DOC>